173 filings
Page 6 of 9
8-K
f3ag2nbacsg2kt0
11 Jun 19
BioPharmX Reports Fiscal First Quarter 2020 Financial Results
4:14pm
8-K
wnq0kxpy04y xy3rq3
16 May 19
Entry into a Material Definitive Agreement
5:06pm
8-K
jd9e8w4t5td2
26 Apr 19
BioPharmX Completes 1-for-25 Reverse Stock Split
4:05pm
8-K
ftzyyf4gtyy 896p98cf
25 Mar 19
Departure of Directors or Certain Officers
8:29am
8-K
xrdgb3
21 Mar 19
BioPharmX Announces $3.9 Million Offering
4:16pm
8-K
qd2966
14 Mar 19
BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results
4:07pm
8-K
c88 yg0zwyh7kzb4
27 Feb 19
BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American
4:27pm
8-K
blp idvugb9jt
4 Feb 19
BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott
5:22pm
8-K
zdabt
20 Dec 18
BioPharmX Receives Notice of Noncompliance from NYSE American
4:40pm
8-K
w1haeq46jxw4wzmv
6 Dec 18
BioPharmX Reports Third Quarter 2019 Financial Results
4:15pm
8-K
7ijf e0uk
21 Nov 18
Entry into a Material Definitive Agreement
8:30am
8-K
09p4l4rsmxn
2 Nov 18
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:00am
8-K
uw1 l116dc
31 Oct 18
Entry into a Material Definitive Agreement
4:10pm
8-K
u9xbf7lf5pzg qe
11 Oct 18
BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea
4:38pm
8-K
mj9o1tg
28 Sep 18
BioPharmX Receives Notice of Noncompliance from NYSE American
9:16am
8-K
rd61lj3
13 Sep 18
BioPharmX Corporation Announces David S. Tierney, MD Joined the Company as Chief Executive Officer
12:00am
8-K
6z3tey66ggq4b3s drww
30 Aug 18
BioPharmX Reports Second Quarter 2019 Financial Results
12:00am
8-K
8x4dbu n9m0hvjj
17 Aug 18
Submission of Matters to a Vote of Security Holders
4:19pm
8-K
llt1pc
7 Jun 18
BioPharmX Reports First Quarter 2019 Financial Results
5:07pm
8-K
pgq981vqb
26 Apr 18
BioPharmX Reports Fourth Quarter and Full Year 2018 Financial Results
4:16pm